# 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

Study · id `cardio:ct-nct01570686` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01570686](<https://clinicaltrials.gov/study/NCT01570686>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01570686

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 589 participants.

## Technical summary

Registry record NCT01570686. Randomized; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2014-01-01.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 589 participants (enrolled count; ClinicalTrials.gov record NCT01570686, source copy `cardio:ctgov-nct01570686-2014-01-22`, retrieved 2026-10-26)
- Start date: 2012-04 (registry gives no type) (ClinicalTrials.gov record NCT01570686, source copy `cardio:ctgov-nct01570686-2014-01-22`, retrieved 2026-10-26)
- Primary completion: 2012-11 (actual) (ClinicalTrials.gov record NCT01570686, source copy `cardio:ctgov-nct01570686-2014-01-22`, retrieved 2026-10-26)
- Completion: 2012-11 (actual) (ClinicalTrials.gov record NCT01570686, source copy `cardio:ctgov-nct01570686-2014-01-22`, retrieved 2026-10-26)
- Results first posted: 2014-01-01 (ClinicalTrials.gov record NCT01570686, source copy `cardio:ctgov-nct01570686-2014-01-22`, retrieved 2026-10-26)
- Countries: United States; Canada; Italy; Puerto Rico; Slovakia; Spain; Taiwan (ClinicalTrials.gov record NCT01570686, source copy `cardio:ctgov-nct01570686-2014-01-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01570686-2014-01-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
- Condition: Hypertension
- Intervention (Drug): Aliskiren
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 632891c96c24a4f871710f0406f8ad2ffda2acdcb31ef2c517c041d8f69f8013
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
